ABT

Prezzo Abbott Laboratories

ABT
$93,47
+$0,67(+0,72%)

*Data last updated: 2026-04-28 19:12 (UTC+8)

As of 2026-04-28 19:12, Abbott Laboratories (ABT) is priced at $93,47, with a total market cap of $161,34B, a P/E ratio of 33,55, and a dividend yield of 2,62%. Today, the stock price fluctuated between $93,27 and $94,78. The current price is 0,21% above the day's low and 1,38% below the day's high, with a trading volume of 13,37M. Over the past 52 weeks, ABT has traded between $90,72 to $139,06, and the current price is -32,78% away from the 52-week high.

ABT Key Stats

Yesterday's Close$91,13
Market Cap$161,34B
Volume13,37M
P/E Ratio33,55
Dividend Yield (TTM)2,62%
Dividend Amount$0,63
Diluted EPS (TTM)3,59
Net Income (FY)$6,52B
Revenue (FY)$44,32B
Earnings Date2026-07-16
EPS Estimate1,28
Revenue Estimate$12,54B
Shares Outstanding1,77B
Beta (1Y)0.782
Ex-Dividend Date2026-04-15
Dividend Payment Date2026-05-15

About ABT

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
SectorHealthcare
IndustryMedical - Devices
CEORobert Ford
HeadquartersAbbott Park,IL,US
Official Websitehttps://www.abbott.com
Employees (FY)115,00K
Average Revenue (1Y)$385,46K
Net Income per Employee$56,73K

Abbott Laboratories (ABT) FAQ

What's the stock price of Abbott Laboratories (ABT) today?

x
Abbott Laboratories (ABT) is currently trading at $93,47, with a 24h change of +0,72%. The 52-week trading range is $90,72–$139,06.

What are the 52-week high and low prices for Abbott Laboratories (ABT)?

x

What is the price-to-earnings (P/E) ratio of Abbott Laboratories (ABT)? What does it indicate?

x

What is the market cap of Abbott Laboratories (ABT)?

x

What is the most recent quarterly earnings per share (EPS) for Abbott Laboratories (ABT)?

x

Should you buy or sell Abbott Laboratories (ABT) now?

x

What factors can affect the stock price of Abbott Laboratories (ABT)?

x

How to buy Abbott Laboratories (ABT) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Hot Posts su Abbott Laboratories (ABT)

TechubNews

TechubNews

04-26 22:01
雅培($ABT)在美国芝加哥举行的"2026心律协会"上,公布了与心律异常治疗技术相关的新临床数据。此次发布因其确认了用于治疗房颤(AFib)的"脉冲场消融"技术以及整个下一代心脏起搏器组合的安全性和有效性而备受关注。 本次数据由共计4项后期临床发布组成。核心是针对复杂房颤患者的"TactiFlex Duo消融导管"的6个月结果、扩展到心脏后壁消融的"Volt PFA系统"数据,以及采用传导系统起搏方式的新型植入式除颤器/无线起搏器研究。雅培正在强化其"综合组合"战略,即能够根据患者状况而非单一方式来治疗各种心律失常。 TactiFlex Duo,在复杂房颤治疗中取得6个月成效 最引人注目的是"FlexPulse IDE"研究结果。在这项针对188名患者进行的临床试验中,雅培的TactiFlex Duo消融导管在6个月的时间点显示,87%的患者未出现记录到的心律失常复发。无主要安全事件的比例为98.3%。 该设备的特点是同时支持射频(RF)和脉冲场消融(PFA)两种能量方式。射频通过热量消除问题组织,而PFA则通过强电脉冲选择性破坏引起异常心律的细胞。其优点在于,医生可以根据患者的解剖结构或疾病复杂程度调整方式。 实际上,在这项研究中,93.3%的患者仅通过PFA接受治疗,93.9%的患者在首次手术后无需额外消融。杜克大学医学中心的Jonathan Piccini在发布会上解释说,TactiFlex Duo为个性化手术提供了灵活性,并且"点对点"方式的PFA在相当多的患者中也显示出效果。 TactiFlex Duo为获得美国食品药品监督管理局(FDA)批准而进行的临床试验正在进行中,今年已在欧洲获得CE认证。 Volt PFA,在心脏后壁消融中也确认安全性 雅培还通过"Volt CE标志扩展队列"试验提供了Volt PFA系统的额外临床证据。本次数据针对的是在标准治疗基础上,还对心脏左心房后壁进行了消融的患者群体。由于房颤不仅发生在肺静脉周围,后壁也可能产生异常电信号,因此后壁消融的有效性和安全性被视为实际操作中的重要评估指标。 根据发布内容,医疗团队将Volt系统的易用性和直观设计视为优势。平均治疗应用次数为每根静脉4.1次,每次后壁隔离(PWI)为10.7次。公司方面解释称,这表明与市售的现有PFA设备相比,其手术流程更高效。未报告与患者或手术相关的并发症。 Volt PFA系统已于去年同时获得美国FDA批准和欧洲CE认证。近年来,在心律失常治疗市场中,PFA作为一项既能减少热损伤又能缩短手术时间的技术而备受关注,因此这一结果被解读为对雅培扩大竞争力具有积极意义。 下一代传导系统起搏设备,早期临床试验结果也呈积极态势 雅培还同时公布了其在传导系统起搏(CSP)领域两款在研设备的初步结果。CSP是一种更接近心脏自然电传导路径进行起搏的方式,有望实现比传统右心室心尖部起搏更生理性的心脏激动。 首先,在"ASCEND CSP IDE"试验中评估的"AltiSync CSP"植入式心律转复除颤器(ICD)导线,基于3个月的数据,达到了预先设定的主要安全性和有效性目标。其显示出97.5%的高安全性特征,无导线相关的重大安全问题,并且满足左束支区域起搏标准的比率为99%。即使在应用更严格标准的情况下,成功率也达到了86%。 除颤性能也引人注目。所有患者的除颤成功率为100%,其中92.5%仅通过20焦耳(J)的首次电击即成功。未报告因不当感知导致的误治疗。亚利桑那州立大学的Rahul Doshi教授评价说,左束支区域起搏与更生理性的激动相关,这一结果提示了将这种优势扩展到植入式心律转复除颤器患者的可能性。 无线起搏器"AVEIR CSP"也开展了首次人体评估 雅培正在开发的"AVEIR CSP"无线起搏器系统的首次人体研究结果也已公布。这项针对19名患者的初步研究的一个月数据显示,其具有高植入成功率,同时,遵循心脏自然电传导路径的起搏传递、稳定的电性能以及双腔环境下一致的设备间通信都得到了确认。 这可以被视为一个早期信号,表明基于电池的无导线起搏器技术未来有可能扩展到更精细的传导系统起搏。虽然仍处于研究初期,但市场对于其能否在减少导线相关并发症的同时实现自然的搏动调节,关注度预计将会增加。 心律失常治疗市场竞争,技术多元化是关键 此次发布表明,雅培正在扩展其涵盖消融导管、球囊型PFA、植入式心律转复除颤器、无线起搏器的心律失常治疗生态系统,而非单一设备。特别是在治疗房颤等复杂心律失常时,患者个体解剖结构和疾病表现各异,"单一解决方案"难以应对这一点正日益凸显。 雅培的Priya Jagasia副总裁表示,心律失常治疗并非一刀切的方法,构建能够涵盖各种节律异常的心血管产品组合至关重要。这些临床结果预计将成为雅培推动后续产品开发和扩大商业应用的重要依据。 尽管部分设备在美国仍仅被批准用于研究用途,但此次临床数据显示雅培在快速增长的心律失常治疗市场中正在提升其影响力。特别是"脉冲场消融"和"传导系统起搏"被视为将决定未来心律治疗标准竞争的下一代核心方向。 TP AI注意事项 使用TokenPost.ai基础语言模型对文章进行了摘要。正文主要内容可能被排除或与事实不符。
0
0
0
0